CTI BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- CTI BioPharma's estimated annual revenue is currently $32.7M per year.
- CTI BioPharma's estimated revenue per employee is $155,000
Employee Data
- CTI BioPharma has 211 Employees.
- CTI BioPharma grew their employee count by -23% last year.
CTI BioPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Information Technology | Reveal Email/Phone |
2 | Executive Director | Reveal Email/Phone |
3 | Associate Director, Professional Relations & Medical Affairs Operations | Reveal Email/Phone |
4 | Associate Director, CMC Project Management | Reveal Email/Phone |
5 | Executive Director, Data Management and Statistical Programming | Reveal Email/Phone |
6 | Senior Director | Reveal Email/Phone |
7 | Executive Director Pharmacovigilance | Reveal Email/Phone |
8 | Associate Director, CMC Project Management and Manufacturing | Reveal Email/Phone |
9 | Director Drug Product Manufacturing | Reveal Email/Phone |
10 | Associate Director, Commercial Enablement & Development, Hematology Training | Reveal Email/Phone |
CTI BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 5 | 0% | N/A | N/A |
#2 | $0.9M | 5 | 0% | N/A | N/A |
#3 | $5.1M | 30 | 11% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 41 | 5% | $16M | N/A |
#7 | $1.1M | 11 | 83% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 8 | 100% | N/A | N/A |
What Is CTI BioPharma?
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.
keywords:N/A
N/A
Total Funding
211
Number of Employees
$32.7M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $46.1M | 211 | 34% | N/A |
#2 | N/A | 211 | 34% | N/A |
#3 | $61.5M | 212 | 6% | $95.5M |
#4 | $63M | 212 | N/A | N/A |
#5 | $66.9M | 212 | -3% | N/A |